Menu

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2019

  1. 24/06/2019
    Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  2. 22/06/2019
    MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019
  3. 14/06/2019
    MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis
  4. 23/05/2019
    MorphoSys to Present at Upcoming Investor Conferences
  5. 22/05/2019
    MorphoSys AG Reports Outcome of Annual General Meeting 2019
  6. 16/05/2019
    MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
  7. 16/05/2019
    MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
    No download available
  8. 07/05/2019
    MorphoSys AG Reports First Quarter 2019 Results
  9. 29/04/2019
    MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
  10. 23/04/2019
    MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2018

  1. 22/03/2018
    Ad hoc: MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering

2017

  1. 30/11/2017
    Ad hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-Mab
    No download available
  2. 23/10/2017
    Ad hoc: MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL
    No download available
  3. 21/07/2017
    Ad hoc: MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma
    No download available
  4. 13/07/2017
    Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis
    No download available

2016

  1. 15/11/2016
    Ad hoc: MorphoSys Raises EUR 115 million in Private Placement
  2. 15/11/2016
    Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares
  3. 01/10/2016
    Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis
  4. 21/04/2016
    Ad hoc: MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab
  5. 04/04/2016
    Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement

Pages

Presentations
and conferences

Wednesday, September 25, 2019
Presentation: 8th Annual Goldman Sachs and Berenberg German Corporate Conference

Jean-Paul Kress presented the Company at the 8th Annual Goldman Sachs and Berenberg German Corporate Conference in Munich, Germany, on September 25, 2019.

DocumentFile info
Company Update1.88 MB

Archive

Date
Title
MP3

2019

  1. 09/25/2019

    Presentation: 8th Annual Goldman Sachs and Berenberg German Corporate Conference

  2. 08/27/2019

    Presentation: Commerzbank Sector Conference 2019

  3. 08/07/2019

    Conference Call and Webcast: Q2 2019 Financial Results

  4. 06/25/2019

    Webcast: Meet the Team

  5. 06/22/2019

    Presentation: ICML in Lugano

  6. 06/12/2019

    Presentation: Goldman Sachs 40th Annual Global Healthcare Conference

  7. 06/06/2019

    Presentation: dbAccess

  8. 06/05/2019

    Webcast: Jefferies Healthcare Conference

  9. 05/20/2019

    Conference call: Q&A session on the headline data of tafasitamab (MOR208)

  10. 05/08/2019

    Conference Call and Webcast: Q1 2019 Financial Results

  11. 04/26/2019

    Presentation: Class of 2018 Biotech IPOs Investor Day

  12. 04/16/2019

    Presentation: Kempen Life Sciences Conference

  13. 03/14/2019

    Year-End 2018 Conference Call and Webcast

  14. 02/28/2019

    Webcast: 8th Annual Leerink Partners Global Healthcare Conference

  15. 01/21/2019

    Presentation: Kepler Chevreux German Corporate Conference

  16. 01/14/2019

    Presentation: Commerzbank German Investment Seminar 2019

  17. 01/09/2019

    Webcast: JPMorgan Annual Healthcare Conference 2019

2018

  1. 12/06/2018

    Presentation: Berenberg European Conference 2018

  2. 12/05/2018

    Webcast: Investor & Analyst Event

  3. 11/28/2018

    Presentation: Piper Jaffray Annual Healthcare Conference

  4. 11/26/2018

    Presentation: German Eigenkapitalforum

  5. 11/22/2018

    Presentation: Bryan Garnier 6th Annual Healthcare Conference

  6. 11/06/2018

    Conference Call and Webcast: Q3 2018 Financial Results

Pages

Pictures

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".